Brisbane, California, United States, Aug 26, 2026
ReviR Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to RTX-117, the company’s investigational oral small-molecule therapy being developed for Charcot-Marie-Tooth disease (CMT). The designation applies broadly to CMT and is not restricted to a particular disease subtype. The FDA’s Rare Pediatric Disease program is intended to encourage the development of therapies for serious or life-threatening rare diseases that predominantly affect children. If RTX-117 is eventually approved and meets applicable statutory and program requirements, ReviR may become eligible for a Rare Pediatric Disease Priority Review Voucher (PRV). Such a voucher can potentially be transferred to another sponsor or used to obtain priority review for a future marketing application, subject to regulatory requirements. The designation adds another regulatory milestone to ReviR’s development program as the biotechnology company advances RTX-117 through Phase 1 clinical development and continues investigating its potential across diseases associated with the integrated stress response pathway.
RTX-117 Targets Integrated Stress Response Pathway
RTX-117 is an investigational orally administered small-molecule therapy developed using ReviR Therapeutics’ proprietary VoyageR AI platform and designed to modulate the integrated stress response (ISR) pathway. The candidate is intended to activate eIF2B, a key regulator involved in protein translation, with the goal of restoring normal messenger RNA translation and protein-expression homeostasis. ReviR is developing the program as a potential disease-modifying approach for CMT while also expanding translational research into other ISR-related diseases, including fibrotic conditions. The company describes RTX-117 as a potential first-in-class therapy, although the candidate remains investigational and has not received marketing approval from the FDA or another regulatory authority. Discovery and molecular design for RTX-117 have also been supported by AI and robotics-enabled drug discovery capabilities, reflecting ReviR’s broader strategy of combining computational approaches with RNA biology to identify small-molecule therapies for difficult-to-treat diseases.
FDA Designation Supports CMT Development
CMT comprises a group of progressive inherited neuromuscular disorders that can emerge during childhood or adolescence and affect peripheral nerves and muscle function. Patients may experience symptoms including leg weakness, muscle wasting, skeletal abnormalities, pain, sensory impairment and delayed motor development. ReviR stated that there are currently no approved disease-modifying therapies for CMT, highlighting the continuing need for therapeutic approaches that address underlying disease mechanisms rather than only managing symptoms. RTX-117 has previously received FDA Orphan Drug Designation for CMT and has obtained clinical trial authorizations in both the United States and China. The program is currently in a Phase 1 clinical trial, with completion anticipated by the end of 2026, according to the company. The RPDD therefore adds another regulatory recognition to an existing development pathway and could provide potential future commercial value through a PRV if the therapy ultimately meets all applicable requirements for approval and voucher eligibility.
Advertisement
ReviR Expands RTX-117 Global Development Strategy
The RPDD also supports ReviR’s broader strategy to develop RNA biology-driven small-molecule therapies across multiple serious diseases. The company is advancing RTX-117 in CMT while also evaluating the candidate in VWM and other ISR-related indications, including fibrotic diseases. ReviR’s broader pipeline includes orally administered small molecules designed to modulate RNA function through mechanisms such as splicing. The company said that clinical and translational experience generated through RTX-117 could help inform future development in genetic diseases, immunology and inflammation, and oncology. For CMT, the immediate focus remains advancing the Phase 1 program and building clinical evidence for the investigational therapy. The FDA’s Rare Pediatric Disease Designation does not constitute evidence of efficacy or approval, but it represents an important regulatory milestone for RTX-117 and recognizes the potential relevance of developing new therapies for serious pediatric-onset rare diseases. As ReviR progresses the program, future clinical data and regulatory interactions will determine whether RTX-117 can advance toward later-stage development and ultimately demonstrate a meaningful therapeutic benefit for patients with CMT.
Source: ReviR Therapeutics press relese
